Core Viewpoint - The trend of Chinese pharmaceutical companies expanding overseas continues to gain momentum, with significant transactions and collaborations expected to persist into 2026, although the total number and value of deals may not surpass those of 2025 [3][20]. Group 1: Overseas Authorization Transactions - In January 2026, Chinese pharmaceutical companies completed 10 overseas authorization transactions, with a notable deal between Rongchang Biopharma and AbbVie involving an upfront payment of $650 million [3]. - The year 2025 marked a record for overseas authorization transactions, with 158 deals totaling $135.7 billion, representing a ten-year high in both quantity and value [7]. - Major transactions in 2025 included a $12 billion strategic cooperation between Innovent Biologics and Takeda, and a $120 billion deal between Hengrui Medicine and GSK, contributing to a total upfront payment of $7 billion for Chinese innovative drugs [8]. Group 2: Market Dynamics and Trends - The U.S. remains the primary trading partner for Chinese pharmaceutical companies, accounting for approximately 48% of all overseas authorization transactions over the past decade [11]. - The increasing urgency for multinational pharmaceutical companies to replenish their pipelines due to impending patent expirations has led to heightened interest in Chinese biotech innovations [11][20]. - China's clinical trial efficiency is significantly higher than that of the U.S., with an average patient enrollment cost of $25,000 compared to $70,000 in the U.S., and a faster enrollment rate [15]. Group 3: Future Outlook - The momentum in overseas transactions is expected to continue, with companies increasingly recognizing the value of Chinese-developed drugs [18][20]. - Despite geopolitical tensions, collaboration between Chinese and U.S. pharmaceutical companies is strengthening, driven by mutual benefits in drug development [20]. - The Chinese pharmaceutical industry is establishing a competitive edge in innovation, although achieving global leadership akin to that in solar energy or automotive sectors may take more time and patience due to the complexities of drug development [20].

Group 1 - The core viewpoint of the articles emphasizes the integration of technological innovation and industrial innovation as a driving force for economic development, particularly in the context of China's strategic industries [1][5][14] - The completion of Beijing Rocket Street marks a significant milestone in commercial aerospace, facilitating a comprehensive ecosystem for rapid demand matching within the industry [1] - The production line for T1000-grade carbon fiber in Shanxi is a breakthrough in high-end materials, crucial for aerospace and defense, overcoming previous technological barriers [3][5] Group 2 - The application of AI in traditional industries, such as dairy production, showcases the deep integration of digital technologies, enhancing efficiency and traceability across the supply chain [7] - The artificial intelligence industry in China is experiencing rapid growth, with a projected scale exceeding 1.2 trillion yuan, reflecting a 30% increase from the previous year [7] - The low-altitude economy is transitioning from pilot projects to large-scale implementation, with significant policy support and the establishment of multiple eVTOL pilot cities [8] Group 3 - The role of enterprises in driving technological innovation is increasingly recognized, with state-owned enterprises significantly increasing R&D investments, reaching 890.16 billion yuan in 2025 [12] - Mechanisms to facilitate the transformation of scientific achievements into practical applications are being strengthened, with universities granting greater ownership of research outcomes to incentivize innovation [12][13] - The collaborative efforts among various stakeholders, including universities and government bodies, are fostering a comprehensive ecosystem for technology transfer and commercialization [14]

"这个势头是可持续的，并不会迅速开始下降。" 2026年，中国新药出海热度不减。 1月尚未结束，中国药企已经完成10笔海外授权交易，其中荣昌生物和艾伯维的交易首付款达到6.5亿美元。 2025年是中国创新药海外交易的大年。第一财经采访的医药和投资机构人士均认为，这种趋势会延续下去。摩根大通大中华区医疗健康行业研究主管黄旸表 示："2026年出海交易数量或者总金额可能难以超过2025年，但会维持强劲的势头。" 首付款超过一级市场融资 最近两年，代谢领域的授权交易升温。2025年，中国药企发生了七笔对外授权。这很大程度上源于礼来和诺和诺德在减重药物市场取得的令人瞩目的成功。 礼来更是成为全球首家市值突破一万亿美元的医药公司，与英伟达、苹果、谷歌等科技巨头并肩而立。 中国代谢领域的交易，是2025年创新药海外授权爆发性增长的缩影。 据医药魔方统计，2025年中国新药对外授权交易158笔，总交易金额1357亿美元，交易数量和金额都达到十年新高。 事实上，2023年和2024年，中国创新药海外授权交易的数量和交易额已经连续突破纪录。医药研发是厚积薄发的过程，即便是临床一期药物，也可能已经经 历了五年左右的研发。2025 ...

Core Insights - The Hong Kong IPO market continues its strong momentum from the previous year, with over 350 companies currently waiting to list as of early 2026 [1][3] - In the first three weeks of the new year, Hong Kong has completed 11 IPOs, raising approximately $4 billion [1] Group 1: IPO Market Dynamics - As of early 2026, the number of companies waiting to list has increased from 316 at the end of 2025 to over 350 within a few weeks [3] - The surge in IPO applications is ongoing, with 16 companies submitting applications to the Hong Kong Stock Exchange in the first seven working days of January 2026 [3] - The IPO pipeline includes leading companies from various sectors, including technology and traditional industries, with notable names such as Ruipai Pet Medical and Anker Innovations [5] Group 2: Geographic and Sectoral Trends - Companies from both first-tier and lower-tier cities in China are actively pursuing listings in Hong Kong, with three companies from Henan province advancing their IPO plans within a week [5] - The IPO market is characterized by a concentration of leading firms across emerging and traditional sectors, with over 70% of listed companies in 2025 coming from information technology, biomedicine, new energy, and high-end manufacturing [12] Group 3: Historical Performance and Future Projections - In 2025, Hong Kong regained its position as the top global IPO market, with 119 IPOs and a total fundraising amount of 2858 billion HKD, marking a 68% increase from 2024 [14] - Predictions for 2026 suggest that the IPO fundraising scale could exceed 300 billion HKD, with estimates ranging from 320 billion to 350 billion HKD and around 150 to 180 companies expected to successfully list [14][12] Group 4: Quality and Market Sentiment - The Hong Kong Stock Exchange emphasizes the importance of IPO quality, acknowledging that the recent surge in applications has led to some lower-quality submissions [16] - There is a growing trend of differentiation in the market, where larger projects and industry leaders are more likely to attract long-term funding, while smaller projects may face challenges based on market conditions and performance [16]

Core Viewpoint - The Shanghai 50 Index has experienced a rare nine consecutive days of decline, marking only the second occurrence in its history, with a total drop of 3.55% during this period [2][8]. Market Performance - As of January 23, the total market capitalization of the Shanghai 50 Index constituents exceeds 27 trillion yuan, accounting for over 20% of the total A-share market capitalization [2]. - The index's previous nine-day decline is compared to a similar event in 2013, which saw a cumulative drop of over 9% [2]. - The recent downturn has led to significant capital outflows from ETFs tracking the Shanghai 50 Index, with net outflows exceeding 41.9 billion yuan from January 13 to 23, primarily from the Huaxia Shanghai 50 ETF [4]. Historical Context - Historically, the Shanghai 50 Index has recorded 33 instances of consecutive declines lasting more than five days, with an average drop of nearly 8% in earlier years [6]. - The average decline during these periods has decreased over time, with the most recent occurrences since 2021 averaging a drop of 4.37% [6]. Future Outlook - Following a series of declines, there is a high probability of a rebound in the A-share market. Historical data indicates that after similar downturns, the Shanghai 50 Index has a greater than 78% chance of experiencing five or more days of gains within ten trading days [8]. - The recent nine-day decline is viewed as a result of style rotation and short-term sentiment release rather than a systemic deterioration of fundamentals [8]. Stock Performance - During the nine-day decline, over 80% of the Shanghai 50 Index constituents experienced at least five days of losses, with notable declines in stocks like Kweichow Moutai and Hengrui Medicine [10]. - Conversely, some stocks, including Langchao Technology and Zijin Mining, have shown resilience, with several companies expected to report positive earnings growth for 2025 [15][18]. - A total of 76 stocks in the electronic, power equipment, and non-ferrous metals sectors are projected to have positive earnings for 2025, with only 11 underperforming relative to the Shanghai Index's 23.4% increase since the beginning of 2025 [15].

最近，A股市场"冰火两重天"，有色金属、国防军工、电子等行业轮番走强，而大盘蓝筹却持续阴跌。 截至1月23日，上证50指数遭遇9连跌；同期，富时中国A50期货亦走出9连跌行情；中证大盘蓝筹25指数表现同样疲软，1月12日至23日，仅有1 月15日微涨，自1月16日起，该指数6连跌。 上证50指数9连跌，历史第二次 截至1月23日，上证50指数成份股总市值超过27万亿元，占全部A股总市值比重超过两成，是大盘蓝筹板块的"晴雨表"。 复盘历史数据，上证50指数仅出现过两次9连跌，第一次发生于2013年5月29日至当年6月13日，区间累计跌幅超过9%；时隔12年，2026年1月13 日至23日的本轮调整，成为该指数历史上第二次9连跌，区间跌幅达3.55%。 伴随指数下行，跟踪上证50指数的ETF资金也大幅流出。1月13日至23日，跟踪上证50的ETF资金净流出额超过419亿元，其中华夏上证50ETF资 金净流出额接近416亿元，资金撤离迹象明显。 从历史走势来看，上证50指数共出现过33次连续5日以上（不含5日）下跌的行情。2010年及以前共11次，其间跌幅均值接近8%，其中2008年6月 3日至同年6月13日（连续 ...

Group 1 - The overall positioning of public funds has become clearer with the completion of the 2025 Q4 reports, showing a notable shift towards cyclical and small-cap growth stocks, while the allocation to Hong Kong stocks has decreased significantly from 19.26% to 16.23% [1] - The decline in the strategic position of Hong Kong stocks within active equity funds contrasts with the upward trend in the A-share market, raising concerns about the future performance of Hong Kong stocks [1] - The A-share market has shown a strong growth style, with significant thematic investment in sectors like commercial aerospace and artificial intelligence hardware, which are less represented in the Hong Kong market [2] Group 2 - Hong Kong stocks are facing dual pressures on liquidity, both from external factors and southbound capital, making them more sensitive to liquidity changes compared to A-shares [3] - Despite a record inflow of 1.4 trillion RMB from southbound capital in 2025, the pace has slowed significantly in Q4, with daily average inflows dropping to 10.9 million HKD in December [3] - The IPO market in Hong Kong has thrived, with 117 IPOs raising 285.9 billion HKD in 2025, marking a return to the top globally, but a potential wave of lock-up expirations could pose challenges [4][5] Group 3 - The upcoming lock-up expirations for major companies listed in the first half of 2025 could lead to significant selling pressure, with an estimated 120 billion HKD in potential unlocks by December [4] - Historical patterns indicate that lock-up expirations have coincided with declines in the Hong Kong market, although strong-performing companies may still attract new investments [5] - The market's current dynamics suggest that while there may be selling pressure from lock-up expirations, the presence of new buying forces could offset this impact [5]

证券日报网讯1月23日，恒瑞医药（600276）在互动平台回答投资者提问时表示，公司稳步推进国际化 战略，在欧盟地区有药品出口销售业务，方式多样，业务收入目前占公司整体营业收入比重较小。 ...

证券研究报告 2026 年 1 月 23 日 星期五 【下周策略】 ◆本周走势回顾 本周指数震荡走强，沪指企稳 4100 点。从周 K 线来看，上证指 数上涨 0.84%，深证成指上涨 1.11%，创业板指下跌 0.34%，科创 50 指数上涨 2.62%，北证 50 指数上涨 2.60%。个股板块涨多跌少，建 筑材料、石油石化、钢铁和基础化工等板块涨幅靠前，医药生物、 食品饮料、非银金融、通信和银行等板块跌幅靠前。 ◆下周大势研判：震荡巩固，春季行情有望延续 从本周市场来看： ◆风险提示： 海外经济超预期下滑，以及中美贸易摩擦超预期恶化，导致外 需回落，国内出口承压；全球主要经济体超预期延长加息周期，高 利率环境使全球经济增速明显放缓，压缩国内资金面；海外信用收 缩引发风险事件，对市场流动性造成冲击，干扰利率和汇率走势。 | 市场近一周走势 | | | | | --- | --- | --- | --- | | 指数名称 | | 周收盘(点) | 涨跌幅 | | 上证指数 | | 4136.16 | 0.84% | | 深证成指 | | 14439.66 | 1.11% | | 创业板 | | 3349.5 ...

Group 1 - The top three companies with the highest AH premium rates are Northeast Electric (00042) at 815.25%, Zhejiang Shibao (01057) at 353.47%, and Sinopec Oilfield Service (01033) at 275.00% [1][2] - The bottom three companies with the lowest AH premium rates are CATL (03750) at -11.83%, China Merchants Bank (03968) at -3.19%, and Heng Rui Medicine (01276) at -3.03% [1][2] - The companies with the highest deviation values are Jinyu Group (02009) at 26.31%, Sanhua Intelligent Control (02050) at 19.65%, and Goldwind Technology (02208) at 18.92% [1][2] Group 2 - The top ten AH stocks by premium rate include companies like Northeast Electric (00042), Zhejiang Shibao (01057), and Sinopec Oilfield Service (01033) [2] - The bottom ten AH stocks by premium rate include companies like CATL (03750), China Merchants Bank (03968), and Heng Rui Medicine (01276) [2] - The top ten AH stocks by deviation value include Jinyu Group (02009), Sanhua Intelligent Control (02050), and Goldwind Technology (02208) [3]